Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Daily Top 10 COVID-19 publications Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe

Tuberculosis

Free Subscription Articles published in Am J Respir Crit Care Med Retrieve available abstracts of 91 articles: HTML format

Single Articles

June 2020
1. 
   Erratum: Tuberculosis Diagnosis in Children Using Xpert Ultra on Different Respiratory Specimens.
   Am J Respir Crit Care Med. 2020;201:1454.
   PubMed    
   
   
   May 2020
2. SCHEUERMANN L, Pei G, Domaszewska T, Zyla J, et al
   Platelets Restrict the Oxidative Burst in Phagocytes and Facilitate Primary Progressive Tuberculosis.
   Am J Respir Crit Care Med. 2020 May 18. doi: 10.1164/rccm.201910-2063.
   PubMed     Abstract available
   
   
   
3. HIBMA JE, Radtke KK, Dorman SE, Jindani A, et al
   Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
   Am J Respir Crit Care Med. 2020 May 15. doi: 10.1164/rccm.201912-2489.
   PubMed     Abstract available
   
   
   April 2020
4. STOUT JE, Turner NA, Belknap RW, Horsburgh CR, et al
   Reply to: Trials of Tuberculosis Preventive Therapy in People with HIV Infection.
   Am J Respir Crit Care Med. 2020 Apr 13. doi: 10.1164/rccm.202003-0855.
   PubMed    
   
   
   
5. SWINDELLS S, Hughes M, Chaisson RE
   Trials of Tuberculosis Preventive Therapy in People with HIV Infection.
   Am J Respir Crit Care Med. 2020 Apr 13. doi: 10.1164/rccm.202003-0761.
   PubMed    
   
   
   March 2020
6. DOOLEY KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, et al
   Reply to: High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis.
   Am J Respir Crit Care Med. 2020 Mar 4. doi: 10.1164/rccm.202002-0359.
   PubMed    
   
   
   
7. DECROO T, de Jong BC, Piubello A, Souleymane MB, et al
   High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis.
   Am J Respir Crit Care Med. 2020 Mar 4. doi: 10.1164/rccm.202001-0201.
   PubMed    
   
   
   February 2020
8. WASSERMAN S, Furin J
   Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with inhA Mutations.
   Am J Respir Crit Care Med. 2020 Feb 20. doi: 10.1164/rccm.202002-0264.
   PubMed    
   
   
   
9. 
   Erratum: Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
   Am J Respir Crit Care Med. 2020;201:500-501.
   PubMed    
   
   
   
10. VERNON A, Bishai W
    Modeling Treatment of Latent Tuberculosis: Shortening the Leap of Faith?
    Am J Respir Crit Care Med. 2020;201:405-406.
    PubMed    
    
    
    
11. ANDRES S, Merker M, Heyckendorf J, Kalsdorf B, et al
    Bedaquiline-resistant Tuberculosis: Dark Clouds on the Horizon.
    Am J Respir Crit Care Med. 2020 Feb 13. doi: 10.1164/rccm.201909-1819.
    PubMed    
    
    
    January 2020
12. DE JAGER VR, Vanker N, van der Merwe L, van Brakel E, et al
    Optimising beta-lactams Against Tuberculosis.
    Am J Respir Crit Care Med. 2020 Jan 10. doi: 10.1164/rccm.201911-2149.
    PubMed    
    
    
    
13. VERRALL AJ, Chaidir L, Ruesen C, Apriani L, et al
    Lower BCG Protection Against Mycobacterium tuberculosis Infection After Exposure to Beijing Strains.
    Am J Respir Crit Care Med. 2020 Jan 8. doi: 10.1164/rccm.201912-2349.
    PubMed    
    
    
    
14. MCSHANE H
    Controlled Human Infection Models - Is it Really Feasible to Give People Tuberculosis?
    Am J Respir Crit Care Med. 2020 Jan 6. doi: 10.1164/rccm.201912-2408.
    PubMed    
    
    
    December 2019
15. GUPTA RK, Lipman M, Jackson C, Sitch A, et al
    Quantitative Interferon Gamma Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis: A Prospective Cohort Study.
    Am J Respir Crit Care Med. 2019 Dec 11. doi: 10.1164/rccm.201905-0969.
    PubMed     Abstract available
    
    
    
16. ABUBAKAR I, Cobelens FG, Rangaka MX
    The Risk of Falsely Declaring Non-Inferiority of Novel Latent Tuberculosis Treatment in Large Trials.
    Am J Respir Crit Care Med. 2019 Dec 9. doi: 10.1164/rccm.201911-2258.
    PubMed    
    
    
    November 2019
17. NAHID P, Mase SR, Migliori GB, Sotgiu G, et al
    Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2019;200:e93-e142.
    PubMed     Abstract available
    
    
    
18. OH JY, Min KH, Lee SY, Shim JJ, et al
    Invasive Endobronchial Mycobacterium kansasii Infection.
    Am J Respir Crit Care Med. 2019;200:e143-e144.
    PubMed    
    
    
    
19. STOUT JE, Turner NA, Belknap RW, Horsburgh CR, et al
    Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling.
    Am J Respir Crit Care Med. 2019 Nov 11. doi: 10.1164/rccm.201908-1606.
    PubMed     Abstract available
    
    
    
20. NARITA M, Sullivan Meissner J, Burzynski J
    Use of Modeling to Inform Tuberculosis Elimination Strategies.
    Am J Respir Crit Care Med. 2019 Nov 7. doi: 10.1164/rccm.201910-2061.
    PubMed    
    
    
    October 2019
21. TEZERA LB, Mansour S, Elkington P
    Reconsidering the Optimal Immune Response to Mycobacterium tuberculosis.
    Am J Respir Crit Care Med. 2019 Oct 28. doi: 10.1164/rccm.201908-1506.
    PubMed     Abstract available
    
    
    
22. FOREMAN TW, Bucsan AN, Mehra S, Peloquin C, et al
    Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques.
    Am J Respir Crit Care Med. 2019 Oct 24. doi: 10.1164/rccm.201903-0646.
    PubMed     Abstract available
    
    
    
23. MENZIES NA, Parriott A, Shrestha S, Dowdy DW, et al
    Comparative Modelling of Tuberculosis Epidemiology and Policy Outcomes in California.
    Am J Respir Crit Care Med. 2019 Oct 18. doi: 10.1164/rccm.201907-1289.
    PubMed     Abstract available
    
    
    
24. AUBRY A, Veziris N
    Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections.
    Am J Respir Crit Care Med. 2019;200:1072-1073.
    PubMed    
    
    
    
25. CHOI HW, Shin JH, Kee SJ, Kwon YS, et al
    Reply to Aubry and Veziris: Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections.
    Am J Respir Crit Care Med. 2019;200:1073-1074.
    PubMed    
    
    
    September 2019
26. SAGAR AS, Dodge DL, Salahuddin M, Warner MT, et al
    Pleural Diseases: Pleurodesis via Indwelling Pleural Catheter, Dasatinib-induced Pleural Effusion, and IL-27 in Tuberculosis Pleural Effusion.
    Am J Respir Crit Care Med. 2019;200:771-773.
    PubMed    
    
    
    August 2019
27. SCHAAF HS, Marais BJ
    The Role of Xpert MTB/RIF Ultra in Diagnosing Pulmonary Tuberculosis in Children.
    Am J Respir Crit Care Med. 2019 Aug 6. doi: 10.1164/rccm.201907-1492.
    PubMed    
    
    
    
28. ZAR HJ, Workman LJ, Prins M, Bateman LJ, et al
    Tuberculosis Diagnosis in Children Using Xpert Ultra on Different Respiratory Specimens.
    Am J Respir Crit Care Med. 2019 Aug 5. doi: 10.1164/rccm.201904-0772.
    PubMed     Abstract available
    
    
    May 2019
29. NIEDERMAN MS, Nair GB, Matt U, Herold S, et al
    Update in Lung Infections and Tuberculosis 2018.
    Am J Respir Crit Care Med. 2019 May 1. doi: 10.1164/rccm.201903-0606.
    PubMed    
    
    
    April 2019
30. KRANZER K, Kalsdorf B, Heyckendorf J, Andres S, et al
    New WHO Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?
    Am J Respir Crit Care Med. 2019 Apr 26. doi: 10.1164/rccm.201902-0260.
    PubMed    
    
    
    March 2019
31. LEE HS, Kee SJ, Shin JH, Kwon YS, et al
    Xpert MTB/RIF Assay as a Substitute for Smear Microscopy in an Intermediate-Burden Setting.
    Am J Respir Crit Care Med. 2019;199:784-794.
    PubMed     Abstract available
    
    
    
32. YOON C, Semitala FC, Cattamanchi A
    Reply to Parker: Implications of Tuberculosis Sputum Culture Test Sensitivity on Accuracy of Other Diagnostic Modalities.
    Am J Respir Crit Care Med. 2019;199:665.
    PubMed    
    
    
    
33. PARKER RA
    Implications of Tuberculosis Sputum Culture Test Sensitivity on Accuracy of Other Diagnostic Modalities.
    Am J Respir Crit Care Med. 2019;199:664.
    PubMed    
    
    
    February 2019
34. GUPTA S, Krug S, Pokkali S, Leanderson T, et al
    Pharmacologic Exhaustion of Suppressor Cells with Tasquinimod Enhances Bacterial Clearance during Tuberculosis.
    Am J Respir Crit Care Med. 2019;199:386-389.
    PubMed    
    
    
    January 2019
35. DHEDA K, Lenders L, Srivastava S, Magombedze G, et al
    Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing.
    Am J Respir Crit Care Med. 2019 Jan 29. doi: 10.1164/rccm.201807-1361.
    PubMed     Abstract available
    
    
    
36. TE BRAKE LHM, Boeree MJ, Aarnoutse RE
    Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2019 Jan 15. doi: 10.1164/rccm.201811-2101.
    PubMed    
    
    
    
37. VELASQUEZ GE, Brooks MB, Coit JM, Sanchez Garavito E, et al
    Reply to: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2019 Jan 15. doi: 10.1164/rccm.201812-2281.
    PubMed    
    
    
    
38. SULIMAN S, Luabeya AKK, Geldenhuys H, Tameris M, et al
    Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
    Am J Respir Crit Care Med. 2019;199:220-231.
    PubMed     Abstract available
    
    
    October 2018
39. SCHLUGER NW
    Tuberculosis Elimination, Research, and Respect for Persons.
    Am J Respir Crit Care Med. 2018 Oct 19. doi: 10.1164/rccm.201809-1623.
    PubMed    
    
    
    
40. KESHAVJEE S, Amanullah F, Cattamanchi A, Chaisson R, et al
    Moving Toward Tuberculosis Elimination: Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.
    Am J Respir Crit Care Med. 2018 Oct 18. doi: 10.1164/rccm.201806-1053.
    PubMed     Abstract available
    
    
    
41. MARTINEZ L, Andrews JR
    Improving Tuberculosis Case Finding in Persons Living with Advanced HIV through New Diagnostic Algorithms.
    Am J Respir Crit Care Med. 2018 Oct 1. doi: 10.1164/rccm.201809-1702.
    PubMed    
    
    
    September 2018
42. YOON C, Semitala FC, Asege L, Katende J, et al
    Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV.
    Am J Respir Crit Care Med. 2018 Sep 7. doi: 10.1164/rccm.201803-0490.
    PubMed     Abstract available
    
    
    August 2018
43. ELKINGTON PT, Bateman AC, Thomas GJ, Ottensmeier CH, et al
    Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.
    Am J Respir Crit Care Med. 2018 Aug 24. doi: 10.1164/rccm.201807-1250.
    PubMed    
    
    
    June 2018
44. VELASQUEZ GE, Brooks MB, Coit JM, Pertinez H, et al
    Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis: A Randomized Controlled Trial.
    Am J Respir Crit Care Med. 2018 Jun 29. doi: 10.1164/rccm.201712-2524.
    PubMed     Abstract available
    
    
    
45. DHEDA K, Lenders L, Magombedze G, Srivastava S, et al
    Drug Penetration Gradients Associated with Acquired Drug Resistance in Tuberculosis Patients.
    Am J Respir Crit Care Med. 2018 Jun 7. doi: 10.1164/rccm.201711-2333.
    PubMed     Abstract available
    
    
    April 2018
46. MONEDERO-RECUERO I
    Drug-resistant Tuberculosis in Europe. What are We Waiting for?
    Am J Respir Crit Care Med. 2018 Apr 18. doi: 10.1164/rccm.201803-0497.
    PubMed    
    
    
    
47. SULIMAN S, Thompson E, Sutherland J, Weiner Rd J, et al
    Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis.
    Am J Respir Crit Care Med. 2018 Apr 6. doi: 10.1164/rccm.201711-2340.
    PubMed     Abstract available
    
    
    March 2018
48. ABUBAKAR I, Gupta RK, Rangaka MX, Lipman M, et al
    Update in Tuberculosis and Non-tuberculous Mycobacteria 2017.
    Am J Respir Crit Care Med. 2018 Mar 14. doi: 10.1164/rccm.201801-0106.
    PubMed    
    
    
    
49. COX D, Keane J
    Platelets and Tuberculosis: Small Cells, Not So Innocent Bystanders.
    Am J Respir Crit Care Med. 2018 Mar 6. doi: 10.1164/rccm.201802-0279.
    PubMed    
    
    
    
50. GUNTHER G, van Leth F, Alexandru S, Altet N, et al
    Clinical Management of Multidrug-resistant Tuberculosis in 16 European Countries.
    Am J Respir Crit Care Med. 2018 Mar 6. doi: 10.1164/rccm.201710-2141.
    PubMed     Abstract available
    
    
    February 2018
51. SCHWANDER S, Keane J
    Cause or Effect - the Elusive Role of Regulatory T Cells in Tuberculosis.
    Am J Respir Crit Care Med. 2018 Feb 28. doi: 10.1164/rccm.201802-0233.
    PubMed    
    
    
    
52. FOX KA, Kirwan DE, Whittington AM, Krishnan N, et al
    Platelets Regulate Pulmonary Inflammation and Tissue Destruction in Tuberculosis.
    Am J Respir Crit Care Med. 2018 Feb 8. doi: 10.1164/rccm.201710-2102.
    PubMed     Abstract available
    
    
    December 2017
53. ERNST JD
    Float Like Bacilli, STING Like a B: Type I Interferons in Tuberculosis.
    Am J Respir Crit Care Med. 2017 Dec 20. doi: 10.1164/rccm.201712-2368.
    PubMed    
    
    
    
54. VARAINE F, Guglielmetti L, Mitnick CD
    Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Am J Respir Crit Care Med. 2017;196:1490-1491.
    PubMed    
    
    
    
55. VAN LETH F, Gunther G, Hoffmann H, Lange C, et al
    Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Am J Respir Crit Care Med. 2017;196:1489-1490.
    PubMed    
    
    
    
56. BARRY PM, Lowenthal P, True L, Henry L, et al
    Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Am J Respir Crit Care Med. 2017;196:1488-1489.
    PubMed    
    
    
    November 2017
57. BENARD A, Sakwa I, Schierloh P, Colom A, et al
    B Cells Producing Type I Interferon Modulate Macrophage Polarization in Tuberculosis.
    Am J Respir Crit Care Med. 2017 Nov 21. doi: 10.1164/rccm.201707-1475.
    PubMed     Abstract available
    
    
    October 2017
58. DIVANGAHI M, Behr MA
    Cracking the Vaccine Code in Tuberculosis.
    Am J Respir Crit Care Med. 2017 Oct 18. doi: 10.1164/rccm.201707-1489.
    PubMed     Abstract available
    
    
    
59. MARTINEZ L, Handel A, Shen Y, Chakraburty S, et al
    A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts.
    Am J Respir Crit Care Med. 2017 Oct 16. doi: 10.1164/rccm.201706-1210.
    PubMed    
    
    
    
60. DHEDA K
    The Multistep Tuberculosis Diagnostic Cascade. More Than Meets the Eye.
    Am J Respir Crit Care Med. 2017;196:809-811.
    PubMed    
    
    
    September 2017
61. ROSSER A, Pareek M, Turapov O, Wiselka MJ, et al
    Differentially Culturable Tubercule Bacilli are Generated During Non-pulmonary Tuberculosis Infection.
    Am J Respir Crit Care Med. 2017 Sep 7. doi: 10.1164/rccm.201705-1048.
    PubMed    
    
    
    August 2017
62. LEWINSOHN D
    An Expanding Role for Environmental Microbes in Shaping the Immune Response to Infection with Mycobacterium Tuberculosis.
    Am J Respir Crit Care Med. 2017 Aug 25. doi: 10.1164/rccm.201708-1599.
    PubMed    
    
    
    
63. BANAEI N, Pai M
    Detecting New Mycobacterium Tuberculosis Infection: Time for a More Nuanced Interpretation of QuantiFERON Conversions.
    Am J Respir Crit Care Med. 2017 Aug 1. doi: 10.1164/rccm.201707-1543.
    PubMed    
    
    
    July 2017
64. ABUBAKAR I, Kloprogge F
    End of the Road for Adjunctive Vitamin D Therapy for Pulmonary Tuberculosis?
    Am J Respir Crit Care Med. 2017 Jul 31. doi: 10.1164/rccm.201707-1509.
    PubMed    
    
    
    
65. SCRIBA TJ, Carpenter C, Carrasco Pro S, Sidney J, et al
    Differential Recognition of Mtb-specific Epitopes as a Function of Tuberculosis Disease History.
    Am J Respir Crit Care Med. 2017 Jul 31. doi: 10.1164/rccm.201706-1208.
    PubMed     Abstract available
    
    
    
66. CLAYTON K, Polak ME, Woelk CH, Elkington P, et al
    Gene Expression Signatures in Tuberculosis Have Greater Overlap with Autoimmune Than Infectious Diseases.
    Am J Respir Crit Care Med. 2017 Jul 28. doi: 10.1164/rccm.201706-1248.
    PubMed    
    
    
    
67. NEMES E, Rozot V, Geldenhuys H, Bilek N, et al
    Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of M. tuberculosis Infection.
    Am J Respir Crit Care Med. 2017 Jul 24. doi: 10.1164/rccm.201704-0817.
    PubMed     Abstract available
    
    
    
68. LESSELLS RJ, Cooke GS, McGrath N, Nicol MP, et al
    Impact of Point-of-care Xpert MTB/RIF on Tuberculosis Treatment Initiation: A Cluster Randomised Trial.
    Am J Respir Crit Care Med. 2017 Jul 20. doi: 10.1164/rccm.201702-0278.
    PubMed     Abstract available
    
    
    
69. GANMAA D, Munkhzul B, Fawzi W, Spiegelman D, et al
    High-Dose Vitamin D3 During Tuberculosis Treatment in Mongolia: A Randomised Controlled Trial.
    Am J Respir Crit Care Med. 2017 Jul 10. doi: 10.1164/rccm.201705-0936.
    PubMed     Abstract available
    
    
    June 2017
70. METCALFE JZ, Streicher E, Theron G, Colman RE, et al
    Cryptic Micro-heteroresistance Explains M. tuberculosis Phenotypic Resistance.
    Am J Respir Crit Care Med. 2017 Jun 14. doi: 10.1164/rccm.201703-0556.
    PubMed     Abstract available
    
    
    
71. BURZYNSKI J
    The Use of Modeling to Compare Tuberculosis Dynamics in Four US States.
    Am J Respir Crit Care Med. 2017 Jun 13. doi: 10.1164/rccm.201705-0963.
    PubMed    
    
    
    
72. GRANDJEAN L
    Investigating the Pathogen Genomic Determinants of Tuberculosis Transmission.
    Am J Respir Crit Care Med. 2017;195:1418-1420.
    PubMed    
    
    
    
73. 
    Erratum: New Guidelines for the Treatment of Drug-Susceptible Tuberculosis from the American Thoracic Society, Centers for Disease Control and Prevention, and the Infectious Diseases Society of America: Now Comes the Hard Part.
    Am J Respir Crit Care Med. 2017;195:1540.
    PubMed    
    
    
    May 2017
74. SHRESTHA S, Hill AN, Marks SM, Dowdy DW, et al
    Comparing Drivers and Dynamics of Tuberculosis (TB) in California, Florida, New York and Texas.
    Am J Respir Crit Care Med. 2017 May 5. doi: 10.1164/rccm.201702-0377.
    PubMed     Abstract available
    
    
    
75. SHAH JA, Musvosvi M, Shey M, Horne DJ, et al
    A Functional TOLLIP Variant is Associated with BCG-Specific Immune Responses and Tuberculosis.
    Am J Respir Crit Care Med. 2017 May 2. doi: 10.1164/rccm.201611-2346.
    PubMed     Abstract available
    
    
    
76. SCHLUGER NW
    AJRCCM: 100-Year Anniversary. Focus on Tuberculosis.
    Am J Respir Crit Care Med. 2017;195:1112-1114.
    PubMed    
    
    
    
77. ALLINSON JP, Mackay AJ, Shah PL
    AJRCCM: 100-Year Anniversary. Special Historical Image Section: Tuberculosis Then and Now.
    Am J Respir Crit Care Med. 2017;195:1118-1123.
    PubMed    
    
    
    
78. VAN ZYL-SMIT RN, Esmail A, Bateman ME, Dawson R, et al
    Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial.
    Am J Respir Crit Care Med. 2017;195:1171-1180.
    PubMed     Abstract available
    
    
    
79. WEDZICHA JA, Brochard LJ, Martinez FD, Martinez FJ, et al
    AJRCCM: 100-Year Anniversary. The Long View and the Fast Lane.
    Am J Respir Crit Care Med. 2017;195:1081-1085.
    PubMed    
    
    
    
80. SAEKI K, Watanabe S, Waseda Y, Kasahara K, et al
    Endobronchial Lesions of Mycobacterium abscessus Infection in an Immunocompromised Patient.
    Am J Respir Crit Care Med. 2017;195:e37-e38.
    PubMed    
    
    
    April 2017
81. DIACON AH, van Brakel E, Lounis N, Meyvisch P, et al
    Triplicate Sputum Cultures for Efficacy Evaluation of Novel Anti-tuberculosis Regimens.
    Am J Respir Crit Care Med. 2017 Apr 27. doi: 10.1164/rccm.201704-0796.
    PubMed    
    
    
    March 2017
82. DEDICOAT MJ, Gunther G, Crudu V, Duarte R, et al
    Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure.
    Am J Respir Crit Care Med. 2017 Mar 21. doi: 10.1164/rccm.201612-2585.
    PubMed    
    
    
    
83. STOUT JE, Dicks KV
    A Breath of Fresh Air for Patients with Pulmonary Nontuberculous Mycobacterial Infection.
    Am J Respir Crit Care Med. 2017;195:716-717.
    PubMed    
    
    
    February 2017
84. 
    What is Tuberculosis (TB)?
    Am J Respir Crit Care Med. 2017;195:P7-P8.
    PubMed    
    
    
    December 2016
85. NEBENZAHL-GUIMARAES H, van Laarhoven A, Farhat MR, Koeken VA, et al
    Transmissible Mycobacterium tuberculosis Strains Share Genetic Markers and Immune Phenotypes.
    Am J Respir Crit Care Med. 2016 Dec 20. doi: 10.1164/rccm.201605-1042.
    PubMed     Abstract available
    
    
    
86. DARTOIS V, Saito K, Warrier T, Nathan C, et al
    New Evidence for the Complexity of the Population Structure of Mycobacterium tuberculosis Increases the Diagnostic and Biologic Challenges.
    Am J Respir Crit Care Med. 2016;194:1448-1451.
    PubMed    
    
    
    November 2016
87. LEU JS, Chen ML, Chang SY, Yu SL, et al
    SP110b Controls Host Immunity and Susceptibility to Tuberculosis.
    Am J Respir Crit Care Med. 2016.
    PubMed     Abstract available
    
    
    
88. HARAUSZ EP, Garcia-Prats AJ, Seddon JA, Schaaf HS, et al
    New/Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis: Practice-Based Recommendations.
    Am J Respir Crit Care Med. 2016.
    PubMed     Abstract available
    
    
    
89. GUGLIELMETTI L, Le Du D, Frechet-Jachym M, Mitnick C, et al
    Preventing Acquired Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis Treatment Requires Optimal Management.
    Am J Respir Crit Care Med. 2016;194:1170-1171.
    PubMed    
    
    
    
90. SAUNDERS MJ, Datta S
    Contact Investigation: A Priority for Tuberculosis Control Programs.
    Am J Respir Crit Care Med. 2016;194:1049-1051.
    PubMed    
    
    
    October 2016
91. VARAINE F, Guglielmetti L, Huerga H, Bonnet M, et al
    Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.
    Am J Respir Crit Care Med. 2016;194:1028-1029.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: